Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. (KTTA): 3 pipeline candidates · ~32 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
32.1 months
D/E 0.03 · 0% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for Pasithea Therapeutics Corp.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$16.9M
Cash
$50.5M
Quarterly Burn
$4.8M
Runway
32.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$6.3M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 4,200,000 | $3.1M |
| adage capital partners gp, l.l.c. | 2,100,000 | $1.6M |
| ameriprise financial inc | 1,350,896 | $1.0M |
| advisorshares investments llc | 337,508 | $250K |
| vanguard capital management llc | 107,630 | $80K |
| geode capital management, llc | 103,985 | $77K |
| renaissance technologies llc | 93,399 | $69K |
| vanguard fiduciary trust co | 43,860 | $33K |
| xtx topco ltd | 33,751 | $25K |
| ubs group ag | 26,149 | $19K |
Showing top 10 of 16 institutional holders of Pasithea Therapeutics Corp.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Pasithea Therapeutics Corp.'s pipeline?
Pasithea Therapeutics Corp. (KTTA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Pasithea Therapeutics Corp.'s lead drug candidate?
Pasithea Therapeutics Corp.'s most advanced tracked candidate is pas-001 (Phase 1) for Schizophrenia.
What is Pasithea Therapeutics Corp.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Pasithea Therapeutics Corp. has approximately 32.1 months of cash runway.
What is Pasithea Therapeutics Corp.'s market capitalization?
Pasithea Therapeutics Corp.'s market capitalization is approximately $16.9M.
Who is the CEO of Pasithea Therapeutics Corp.?
Dr. Tiago Reis Marques M.D., Ph.D. is the chief executive officer of Pasithea Therapeutics Corp. (KTTA).
Get the full picture on Pasithea Therapeutics Corp.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.